PMID- 38416391
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240310
IS  - 2198-6576 (Print)
IS  - 2198-6584 (Electronic)
IS  - 2198-6576 (Linking)
VI  - 11
IP  - 2
DP  - 2024 Apr
TI  - Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction 
      at 1 Year in the Canadian Real-World APPRAISE Study.
PG  - 443-455
LID - 10.1007/s40744-024-00641-w [doi]
AB  - INTRODUCTION: The APPRAISE study was conducted to better understand the 12-month 
      effectiveness, tolerability, and patient satisfaction with apremilast treatment 
      for patients with psoriatic arthritis (PsA) in real-world settings. METHODS: 
      APPRAISE (NCT03608657), a prospective, multicenter, observational study, enrolled 
      adults with active PsA prescribed apremilast per routine care between July 2018 
      and March 2020. Patients were followed for 12 months with visits suggested every 
      4 months. The primary outcome measure was achievement of remission (REM) or low 
      disease activity (LDA), defined as a Clinical Disease Activity Index for 
      Psoriatic Arthritis (cDAPSA) score </= 13. RESULTS: Of the 102 patients who 
      enrolled, 45 (44.1%) discontinued the study by 12 months. Most patients (75.5%) 
      had moderate or high disease activity, and 24.5% were in REM/LDA at baseline 
      based on cDAPSA score. Achievement of cDAPSA REM/LDA was 63.7%, 67.2%, and 53.8% 
      at months 4, 8, and 12, respectively. In those continuing in the study, 
      significant improvements were seen in swollen and tender joint counts, pain 
      visual analog scale, psoriasis body surface area, and complete dactylitis 
      resolution. Enthesitis reduction was also observed. Improvements in treatment 
      satisfaction and patient-reported outcomes, including Health Assessment 
      Questionnaire-Disability Index and the 36-item Short Form physical and mental 
      component scores, were observed over 12 months. The proportion of patients 
      achieving a Patient-Acceptable Symptom State (PASS) increased significantly from 
      baseline at months 4, 8, and 12 (P < 0.001). Apremilast was well tolerated; the 
      most frequent adverse events (AEs) leading to discontinuation were diarrhea 
      (9/102 [8.8%]), nausea (4/102 [3.9%]), and migraine (4/102 [3.9%]). CONCLUSION: 
      In this real-world study conducted in Canadian rheumatology clinics, apremilast 
      demonstrated clinical effectiveness in patients with active PsA, along with 
      patient satisfaction with treatment. Safety findings were consistent with 
      previously reported clinical data. TRIAL REGISTRATION: ClinicalTrials.gov 
      identifier, NCT03608657.
CI  - (c) 2024. The Author(s).
FAU - Chandran, Vinod
AU  - Chandran V
AUID- ORCID: 0000-0002-8297-0275
AD  - Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western 
      Hospital, 399 Bathurst St., 1E 416, Toronto, ON, M5T 2S8, Canada. 
      vinod.chandran@uhnresearch.ca.
FAU - Bessette, Louis
AU  - Bessette L
AUID- ORCID: 0000-0002-6834-2731
AD  - Laval University, 2325 Rue de l'Universite, Quebec, QC, G1V 0A6, Canada.
FAU - Thorne, Carter
AU  - Thorne C
AUID- ORCID: 0000-0002-1721-190X
AD  - Centre of Arthritis Excellence, 108-465 Davis Drive, Newmarket, ON, L3Y 7T9, 
      Canada.
FAU - Sheriff, Maqbool
AU  - Sheriff M
AUID- ORCID: 0009-0004-9310-0584
AD  - Nanaimo Regional General Hospital, 1200 Dufferin Crescent, Nanaimo, BC, V9S 2B7, 
      Canada.
FAU - Rahman, Proton
AU  - Rahman P
AUID- ORCID: 0000-0002-4521-2029
AD  - Memorial University of Newfoundland, St John's, NL, Canada.
FAU - Gladman, Dafna D
AU  - Gladman DD
AUID- ORCID: 0000-0002-9074-0592
AD  - Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western 
      Hospital, 399 Bathurst St., 1E 416, Toronto, ON, M5T 2S8, Canada.
FAU - Anwar, Sabeen
AU  - Anwar S
AUID- ORCID: 0000-0002-2923-9862
AD  - Windsor Regional Hospital, 1030 Ouellette Ave, Windsor, ON, N9A 1E1, Canada.
FAU - Jelley, Jennifer
AU  - Jelley J
AUID- ORCID: 0009-0005-1417-1075
AD  - Amgen Canada Inc., 6775 Financial Dr #300, Mississauga, ON, L5N 0A4, Canada.
FAU - Gaudreau, Anne-Julie
AU  - Gaudreau AJ
AUID- ORCID: 0009-0004-4853-7445
AD  - Amgen Canada Inc., 6775 Financial Dr #300, Mississauga, ON, L5N 0A4, Canada.
FAU - Chohan, Manprit
AU  - Chohan M
AUID- ORCID: 0009-0003-0464-871X
AD  - Amgen Canada Inc., 6775 Financial Dr #300, Mississauga, ON, L5N 0A4, Canada.
FAU - Sampalis, John S
AU  - Sampalis JS
AUID- ORCID: 0000-0002-0075-369X
AD  - McGill University and JSS Medical Research, 9400 Henri Bourassa Blvd W, 
      Saint-Laurent, QC, H4S 1N8, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03608657
PT  - Journal Article
DEP - 20240228
PL  - England
TA  - Rheumatol Ther
JT  - Rheumatology and therapy
JID - 101674543
PMC - PMC10920604
OTO - NOTNLM
OT  - Apremilast
OT  - Psoriatic arthritis
OT  - Rheumatology
COIS- Vinod Chandran has received grant/research support from and/or served as a 
      consultant for AbbVie, Amgen Inc., Bristol Myers Squibb, Celgene, Eli Lilly, 
      Janssen, Novartis, Pfizer, and UCB Pharma. His spouse is an employee of 
      AstraZeneca. Louis Bessette has received grant/research support from and/or 
      served as a consultant for AbbVie, Amgen Inc., Bristol Myers Squibb, Celgene, Eli 
      Lilly, Janssen, Merck, Pfizer, Sanofi, Novartis, and UCB Pharma. Carter Thorne 
      has served on an advisory board for AbbVie, Amgen Inc., Celgene, Eli Lilly, 
      Medexus/Medac, Merck, Novartis, Pfizer, Sandoz, and Sanofi; and has served as a 
      consultant for Centocor, Medexus/Medac, and Merck. Maqbool Sheriff has served on 
      an advisory board and received honoraria from AbbVie, Celgene, Eli Lilly, 
      Janssen, Merck, Pfizer, and Sandoz. Proton Rahman has served as a speaker for and 
      received honoraria from AbbVie, Amgen Inc., Celgene, Eli Lilly, Janssen, Merck, 
      Novartis, Pfizer, and UCB Pharma. Dafna D. Gladman has received grant/research 
      support from or served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, 
      Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. Sabeen 
      Anwar has received grant/research support from AbbVie, Amgen Inc., Eli Lilly, 
      Janssen, and Pfizer; and has served as a speaker or consultant for AbbVie, Amgen 
      Inc., Bristol Myers Squibb, Novartis, and Pfizer. Jennifer Jelley, Anne-Julie 
      Gaudreau, and Manprit Chohan are employees of and stockholders in Amgen Inc. John 
      S. Sampalis is an employee of JSS Medical Research.
EDAT- 2024/02/28 12:43
MHDA- 2024/02/28 12:44
PMCR- 2024/02/28
CRDT- 2024/02/28 11:16
PHST- 2023/09/29 00:00 [received]
PHST- 2024/01/16 00:00 [accepted]
PHST- 2024/02/28 12:44 [medline]
PHST- 2024/02/28 12:43 [pubmed]
PHST- 2024/02/28 11:16 [entrez]
PHST- 2024/02/28 00:00 [pmc-release]
AID - 10.1007/s40744-024-00641-w [pii]
AID - 641 [pii]
AID - 10.1007/s40744-024-00641-w [doi]
PST - ppublish
SO  - Rheumatol Ther. 2024 Apr;11(2):443-455. doi: 10.1007/s40744-024-00641-w. Epub 
      2024 Feb 28.